The Partnership to Advance Cardio Health made the following statement regarding the Institute for Clinical and Economic Review’s (ICER) updated analysis on the value of PCSK9 inhibitors, a breakthrough treatment for patients with high cholesterol.
The Institute for Clinical and Economic Review (ICER) has responded positively to National Forum recommendations to obtain input and include data from several National Forum members for ICER’s upcoming New Evidence Update to its 2015 review on the effectiveness and value of PCSK9 inhibitors. The recommendations stem from the National Forum’s Value & Access Initiative, which has assembled patient, provider, public health, payer and pharma/biotech groups to achieve a consensus goal: Enhance health and well-being by supporting people’s access to evidence-based care that is appropriate for them.
April 3, 2017 letter from the Partnership to Improve Patient Care (PIPC), with support from other patient advocate organizations, providing feedback on the proposed revisions to the Institute for Clinical and Economic Review’s (ICER) value framework.
Traditionally, resource utilization and value considerations have been explicitly excluded from practice guidelines and performance measures formulations, although they often are implicitly considered. This document challenges this historical policy. With accelerating healthcare costs and the desire to achieve the best value (health benefit for every dollar spent), there is growing recognition of the need for more explicit and transparent assessment of the value of health care.